5350-50-5

Basic information

• Product Name: 7-CHLORO-4-HYDROXY-3-NITROQUINOLINE
• Synonyms: 7-CHLORO-4-HYDROXY-3-NITROQUINOLINE ;7-Chloro-3-nitro-quinolin-4-ol;4-Quinolinol, 7-chloro-3-nitro-;7-chloro-3-nitro-4-Quinolinol;NSC 35;NSC 4471;7-Chloro-3-nitro-1H-quinolin-4-one
• CAS NO: 5350-50-5
• Molecular Formula: C₉H₅ClN₂O₃
• Molecular Weight: 224.6006
• Mol File: 5350-50-5.mol

Chemical Properties

• Boiling Point: 350.5°Cat760mmHg
• Flash Point: 165.8°C
• Appearance: /
• Density: 1.58g/cm³
• Vapor Pressure: 4.38E-05mmHg at 25°C
• Refractive Index: 1.67
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 7-CHLORO-4-HYDROXY-3-NITROQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-CHLORO-4-HYDROXY-3-NITROQUINOLINE(5350-50-5)
• EPA Substance Registry System: 7-CHLORO-4-HYDROXY-3-NITROQUINOLINE(5350-50-5)

Safety Data

• Hazardous Substances Data: 5350-50-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
7-Chloro-4-hydroxy-3-nitroquinoline is used as a key intermediate in the synthesis of various medicines. Its unique structure and properties contribute to the development of new pharmaceutical compounds with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 7-Chloro-4-hydroxy-3-nitroquinoline serves as an essential component in the production of pesticides. Its incorporation into these formulations enhances their effectiveness in controlling pests and diseases in agricultural settings.
Used in Medicinal Chemistry Research:
Due to its pharmacological activities and biological properties, 7-Chloro-4-hydroxy-3-nitroquinoline holds potential for applications in the field of medicinal chemistry. Researchers utilize 7-CHLORO-4-HYDROXY-3-NITROQUINOLINE to explore its interactions with biological targets and develop novel therapeutic agents.

InChI:InChI=1/C9H5ClN2O3/c10-5-1-2-6-7(3-5)11-4-8(9(6)13)12(14)15/h1-4H,(H,11,13)

Upstream product

• 86-98-6 4,7-dichloroquinoline 
• 86-99-7 7-chloro-4-hydroxylquinoline 

Downstream Products

• 22931-74-4 4,7-dichloro-3-nitroquinoline 
• 84973-05-7 3-bromo-7-chloroquinoline 
• 860195-22-8 (7-chloro-3-nitro-[4]quinolyl)-phenyl-amine 
• 70237-22-8 4,7-dichloro-3-iodoquinoline 

Relevant articles and documents

IMIDAZOQUINOLINE COMPOUNDS AND PRODRUGS THEREOF

The present technology is directed to TLR7 and TLR8 agonist compounds, compositions, and methods of using the same for the treatment of cancers and as vaccine adjuvants.

INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENTS

This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating or preventing inappropriate activation of a type I interferon (IFN) response in a subject in need thereof.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

INHIBITORS OF MALT1 AND USES THEREOF

Provided herein are compounds that inhibit MALTl, a protein whose activity is responsible for constitutive NF-κΒ signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating MALTl -related diseases and disorders (e.g., cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.

Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?

The syntheses and antiplasmodial activities of various substituted aminoquinolines coupled to an adamantane carrier are described. The compounds exhibited pronounced in vitro and in vivo activity against Plasmodium berghei in the Thompson test. Tethering a fluorine atom to the aminoquinoline C(3) position afforded fluoroaminoquinolines that act as intrahepatocytic parasite inhibitors, with compound 25 having an IC50 = 0.31 μM and reducing the liver load in mice by up to 92% at 80 mg/kg dose. Screening our peroxides as inhibitors of liver stage infection revealed that the tetraoxane pharmacophore itself is also an excellent liver stage P. berghei inhibitor (78: IC50 = 0.33 μM). Up to 91% reduction of the parasite liver load in mice was achieved at 100 mg/kg. Examination of tetraoxane 78 against the transgenic 3D7 strain expressing luciferase under a gametocyte-specific promoter revealed its activity against stage IV-V Plasmodium falciparum gametocytes (IC50 = 1.16 ± 0.37 μM). To the best of our knowledge, compounds 25 and 78 are the first examples of either an 4-aminoquinoline or a tetraoxane liver stage inhibitors.

1H-IMIDAZO[4,5-c]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoloquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.

Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof

Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.